| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
4'-Methoxypuerarin does not have a well-defined specific pharmacological target. As an isoflavone derivative, it likely modulates multiple signaling pathways involved in oxidative stress, inflammation, and cell survival. Its methoxy group at the 4' position enhances its lipophilicity and biological stability.
|
|---|---|
| ln Vitro |
In vitro, 4'-Methoxypuerarin demonstrates antioxidant, anti-inflammatory, cardioprotective, and neuroprotective activities. Specific potency data, such as IC50 values, are not widely reported. Its activity is consistent with the broader class of isoflavones, which are known for these effects.
|
| ln Vivo |
In vivo, 4'-Methoxypuerarin is believed to contribute to the pharmacological effects of Pueraria lobata, which is used in traditional medicine for cardiovascular and metabolic disorders. Its cardioprotective and neuroprotective effects suggest potential for treating cardiovascular and neurodegenerative diseases.
|
| Enzyme Assay |
The in vitro antioxidant assay for 4'-Methoxypuerarin involves measuring its ability to scavenge free radicals, such as DPPH or ABTS. For anti-inflammatory activity, its ability to inhibit the production of inflammatory mediators in stimulated macrophages can be measured.
|
| Cell Assay |
In vitro cell culture studies for 4'-Methoxypuerarin utilize various cell lines to study its bioactivity. Its cardioprotective effects can be studied in cardiomyocytes, and its neuroprotective effects can be studied in neuronal cells.
|
| Animal Protocol |
In vivo animal experiments for 4'-Methoxypuerarin could be performed in models of cardiovascular disease, inflammation, or neurodegeneration. The compound would be administered orally or intraperitoneally, and endpoints such as infarct size, inflammatory markers, or behavioral outcomes would be assessed.
|
| ADME/Pharmacokinetics |
4'-Methoxypuerarin has a molecular weight of 430.40 g/mol and is soluble in DMSO. It is typically stored as a powder at 2-8°C. Its purity is ≥98%.
|
| Toxicity/Toxicokinetics |
Toxicological data for 4'-Methoxypuerarin are limited, as it is a research compound. As a natural isoflavone, it is generally considered to have low toxicity. However, comprehensive toxicity studies are not available.
|
| References | |
| Additional Infomation |
4'-Methoxypuerarin is a research compound with no clinical approval. It is a valuable tool for studying the pharmacology of isoflavones and their potential applications in cardiovascular and neurodegenerative diseases.
|
| Molecular Formula |
C22H22O9
|
|---|---|
| Molecular Weight |
430.4047
|
| Exact Mass |
430.126
|
| CAS # |
92117-94-7
|
| PubChem CID |
5319486
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
661.7±55.0 °C at 760 mmHg
|
| Flash Point |
232.2±25.0 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.676
|
| LogP |
2.14
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
31
|
| Complexity |
674
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
COC1=CC=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O
|
| InChi Key |
UWRLUNPRLSNXRR-PGPONNFDSA-N
|
| InChi Code |
InChI=1S/C22H22O9/c1-29-11-4-2-10(3-5-11)13-9-30-21-12(17(13)25)6-7-14(24)16(21)22-20(28)19(27)18(26)15(8-23)31-22/h2-7,9,15,18-20,22-24,26-28H,8H2,1H3/t15-,18-,19+,20-,22+/m1/s1
|
| Chemical Name |
7-hydroxy-3-(4-methoxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~232.34 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.81 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3234 mL | 11.6171 mL | 23.2342 mL | |
| 5 mM | 0.4647 mL | 2.3234 mL | 4.6468 mL | |
| 10 mM | 0.2323 mL | 1.1617 mL | 2.3234 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
